<DOC>
	<DOC>NCT01369485</DOC>
	<brief_summary>The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).</brief_summary>
	<brief_title>Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Males and Females, at least 18 years of age Failure on primary OAB treatment, such as behavior modification or fluid/diet management, AND at least one (1) anticholinergic drug (unless patient was contraindicated for anticholinergic use) Symptoms of overactive bladder for at least 6 months An average of one (1) or more urgency (urinary) incontinence episodes per 24hours, over a 3day period, confirmed by the 3day baseline voiding diary, with a maximum of 12 urgency (urinary) incontinence episodes per 24hours Dexterity and ability to place and operate the device Females of childbearing capability agrees to use a reliable form of birth control for the duration of the trial An average of eight (8) or more voids per 24hours, over a 3day period, confirmed by the 3day baseline voiding diary Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the baseline voiding diary Signed and dated the IRBapproved Informed Consent document. Dysfunctional voiding symptoms unrelated to OAB, such as clinically significant bladder outlet obstruction, and urinary retention (pvr &gt; 100 cc) Morbidly obese, defined as having Body Mass Index (BMI) &gt; 40 kg/m2 Stress predominant mixed urinary incontinence Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury and uncontrolled epilepsy. Pelvic surgery (such as suburethral sling, pelvic floor repair) within the past 6 months Intravesical or urethral sphincter Botulinum Toxin Type A injections within the past 12 months Any neuromodulation therapy for overactive bladder within the past 3 months Failure to respond to previous neuromodulation therapy for overactive bladder Leading edge of any vaginal prolapse is beyond hymenel ring. Prior periurethral or transurethral bulking agent injections for bladder problems within the past 12 months. Any skin conditions affecting treatment or assessment of the treatment sites History of lower back surgery or injury that could impact placement of the patch, or where underlying scar tissue or nerve damage may impact treatment. Presence of an implanted electromedical device (e.g. pacemaker, defibrillator, InterStimÂ®, etc.), or any metallic implant in the lower back. Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to become pregnant during the course of the study. Known latex allergies, or allergies or hypersensitivity to patch materials that will be in contact with the body (e.g., hydrogel, acrylicbased adhesive, polyurethane). Uncontrolled diabetes and/or diabetes with peripheral neuropathy. Current Urinary Tract Infection (UTI) or history of recurrent UTIs (&gt;3 UTIs in the past year). History of lower tract genitourinary malignancies within the last 6 months or any previous pelvic radiation. Any clinically significant systemic disease or condition that in the opinion of the Investigator would make the patient unsuitable for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Urinary Incontinence</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Frequency</keyword>
	<keyword>Urgency</keyword>
</DOC>